Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2004

View Archived Issues

The Prous Science Broadcasting Division presents coverage of the AAOS meeting

NeuroSearch reports R&D milestones in 2003

GTx highlights 2003 achievements

Enrollment completed in PISCES study of Medstent

Generex, PharmaBrand to establish joint venture for Oralin in Latin America

Aventis returns Dynepo rights to TKT

Additional data requested prior to 510(k) clearance of UPlink(R) system

Evotec and Panacos enter HIV medicinal chemistry collaboration

Prous Science announces new multimedia animation highlighting NPC1L1 as a target for ezetimibe

Orathecin NDA accepted for filing

Peptimmune/Medivir Cathepsin S program designates candidate drug

Cloretazine enters phase II AML/MDS trial

InterMune to copromote Aralast

AEG-35156 enters phase I trials

Approval for new presentations of Gonal-f

International Partnership for Microbicides to develop Tibotec's TMC-120

Use of reboxetine for hot flashes claimed by patent

Ranbaxy patents series of novel muscarinic receptor antagonists

DeveloGen cites use of TGF BETA IG-H3 protein in treatment of obesity, diabetes, metabolic syndrome

G-protein-coupled receptor 45 possible target for treatment of cancer, other disorders

Substituted phenylindoles for treatment of HIV disclosed in recent patent

Ajinomoto reports novel series of antidiabetic compounds

Potent cytotoxic nucleoside for HCC therapy

Duloxetine demonstrates efficacy in women with stress urinary incontinence

Nereus presents data on NPI-0052, a novel, oral proteasome inhibitor

Enhancement of paclitaxel anticancer activity with HSP70 inducer STA-4783

Stem cell therapy effective in urinary incontinence patients

Doxazosin reduces bladder cancer tumor growth in vivo

RGB-286199, a potent, broad-spectrum cyclin-dependent kinase inhibitor

Promising compounds by the international Malarial Medicines Venture

BXL-353 inhibits testosterone-stimulated prostate growth in vivo

ECO-04601 demonstrates broad antitumor activity in various tumor cell lines

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...